Metastatic Cancer: Mechanism of Metastasis & Tumor Staging

The TNM classification system is used to stage cancer and determine prognosis, where T indicates tumor size (T0: no tumor, T1: ≤1cm, T2: >1-2cm, T3: >2-5cm, T4: >5cm), N indicates lymph node involvement (N0: none, N1: single node, N2: multiple nodes but not all, N3: all nodes involved), and M indicates metastasis (M0: none, M1: present). This staging system helps predict patient outcomes, with Stage I having 50-90% survival rates, Stage II having 20-30%, and Stage IV having approximately 5% survival rates.

TNM is the universal international classification system for staging any malignant process, developed by French scientist Denoix in 1942. T stands for tumor (size and extent), N for lymph node involvement, and M for metastasis. This standardized language allows oncologists worldwide to communicate about cancer staging regardless of nationality or language. The classification is assigned once at diagnosis and rarely changed during treatment unless there is significant disease progression. TNM staging determines treatment planning and prognosis for each patient.

Clinical examination positions: sitting semi-recumbent for inspection, supine for palpation. Arm positions: by side for mobility, raised above head for fixity to pectoralis major. Fixity to chest wall (ribs, intercostal muscles, serratus anterior) is checked by forward bending - if breast doesn't fall forward, tumor has infiltrated chest wall. Triple assessment includes clinical, radiological (mammography - always bilateral, CC and MLO views), and pathological (core biopsy preferred over FNAC for invasion/grade/receptor status). Multifocal (multiple lesions in one quadrant) vs multicentric (different quadrants, >4 cm apart). TNM staging: T1 <2 cm, T2 2-5 cm, T3 >5 cm. T4 includes T4A (chest wall), T4B (skin involvement - peau d'orange, satellite nodules, ulceration), T4C (both), T4D (inflammatory carcinoma). N1 (mobile axillary nodes), N2 (fixed), N3 (supraclavicular/infraclavicular/internal mammary). M0 (no metastasis), M1 (distant). Early breast cancer (Stage 1-2) treatment: modified radical mastectomy (removes breast, nipple complex, skin over tumor, and level 1-2 axillary lymph nodes) or breast conservation surgery (removes tumor with 1 cm margin plus radiotherapy). BCS is oncologically equivalent to mastectomy with better psychological quality of life. Contraindications for BCS: multicentricity, central/nipple complex tumors, BRCA mutation, persistently positive margins. Sentinel lymph node biopsy identifies first draining node using methylene blue or radioactive sulfur colloid. If negative, no axillary dissection needed. If positive, level 1-2 nodes are removed. Modified radical mastectomy approaches: Axillary clearance (retract pectoralis minor), Scapular (split pectoralis minor), Exin (retract without splitting). Level 3 dissection is intraoperative if level 2 nodes are hard. Boundaries: superiorly axillary vein, inferiorly latissimus dorsi pedicle, anteriorly pectoralis major, posteriorly latissimus dorsi, floor subscapularis. Structures to preserve: long thoracic nerve of Bell (damage causes winging), latissimus dorsi pedicle and nerve. Minimum 10 lymph nodes for adequate staging.

Cancer tumors are graded based on how abnormal cells appear under a microscope, with Grade I being well-differentiated (low grade, slow-growing) and Grade IV being undifferentiated (high grade, fast-spreading); cancer is staged using the TNM system (Tumor, Nodal involvement, Metastasis) which categorizes the primary tumor size and invasion (T), regional lymph node spread (N), and distant metastasis (M) to determine treatment approaches and prognosis.

T staging: T1 (<2cm), T2 (2-5cm), T3 (>5cm), T4 (invasive to chest wall/skin). N staging: N0 (no node involvement), N1 (1-3 axillary nodes), N2 (≥4 axillary or any clavicular nodes), N3 (multiple nodes). M staging: M0 (no distant metastasis), M1 (distant metastasis).

MMPs promote tumor progression through multiple mechanisms: releasing growth factors bound to the matrix, degrading the basement membrane to enable invasion, activating other MMPs, and activating integrins on cancer cells. The tumor microenvironment contains multiple cell types (tumor cells, stromal cells, immune cells) that contribute to MMP production. MMPs also help cancer cells evade immune recognition by degrading components of the extracellular matrix that would otherwise present tumor antigens to immune cells. MMP inhibitors have been developed as cancer drugs, but clinical efficacy has been limited. Alternative approaches target upstream regulators like HIF or NF-κB. MMPs represent important therapeutic targets for preventing tumor invasion and metastasis. The balance between MMPs and their inhibitors determines the extent of matrix remodeling and tumor progression.

As tumors grow, cells become remote from blood supply, creating hypoxic conditions that trigger hypoxia-inducible factors (HIF). HIF activates genes releasing VEGF and FGF2, stimulating angiogenesis. Normally controlled by angiostatin and thrombospondin, this balance is disrupted in tumors, allowing increased blood supply and metastasis. Angiogenesis produces abnormal, disorganized, leaky blood vessels with integrins protecting new cells from apoptosis. Matrix metalloproteinases (MMPs) must break down basement membranes for angiogenesis to begin. Angiogenesis inhibitors are safer than cytotoxic agents but work best in combination. Drugs can be delivered via liposomes that exploit leaky tumor vasculature.

Angiogenesis inhibition in metastatic colorectal cancer targets the VEGF pathway to block tumor blood vessel formation; the process involves tumor hypoxia triggering VEGF production, which promotes chaotic vasculature, and antiangiogenic agents like bevacizumab, aflibercept, ramucirumab, and regorafenib work through different mechanisms (monoclonal antibodies, fusion proteins, tyrosine kinase inhibitors) to inhibit VEGF signaling, with clinical evidence showing improved survival and progression-free survival in both first-line and second-line treatment settings.

Angiogenesis inhibitors are targeted anticancer drugs that block the formation of new blood vessels (angiogenesis), which tumors need to grow and spread; these drugs work by inhibiting vascular endothelial growth factor (VEGF) signaling, thereby cutting off the blood supply to tumors and preventing their growth and metastasis. A key example is bevacizumab, a monoclonal antibody that binds to VEGF and prevents it from activating its receptor, thus stopping the angiogenesis process. These targeted therapies offer advantages over conventional chemotherapy by specifically targeting cancer-associated pathways while minimizing damage to normal cells, though they can cause side effects such as increased risk of arterial thromboembolism and bleeding.

Angiogenesis inhibitors targeting VEGF and FGFR pathways represent important therapeutic strategies in metastatic colorectal cancer, but their clinical application requires careful consideration of toxicity profiles, optimal dosing combinations, and the absence of definitive predictive biomarkers; while these agents offer significant clinical benefit, their integration into treatment algorithms must balance efficacy against manageable side effects, particularly when combining multiple targeted agents.

The seed and soil hypothesis, introduced by Stephen Paget in the late 1800s, proposes that cancer metastasis depends on specific interactions between primary tumors ('seeds') and receptive target organs ('soil'). For many years discounted in favor of anatomical explanations, this concept has been validated by modern research showing that soluble factors from primary tumors circulate and prime distant organs to become receptive to metastatic cells. Tumor-derived exosomes—nano-sized particles carrying DNA, RNA, and proteins—function like hormones, traveling through the bloodstream to condition distant organs before metastatic cells arrive. This creates a receptive microenvironment that facilitates metastatic colonization, explaining why certain organs are preferentially targeted by specific cancers.

Cancer cell dissemination routes include lymphatic spread (to lymph nodes) and hematogenous spread (through blood circulation). Circulating tumor cells (CTCs) can be detected in blood for prognosis. The seed and soil hypothesis of metastasis proposes that cancer cells (seeds) must find compatible microenvironments (soil) to grow. Different cancers preferentially metastasize to specific organs based on microenvironment compatibility. This explains why certain cancers commonly metastasize to specific organs (e.g., lung cancer to brain, breast cancer to bone).

CTCs employ multiple survival strategies: clustering, platelet coating, and immunosuppressive signaling. Tumor cells secrete exosomes containing microRNAs that prepare pre-metastatic niches in distant organs. Organotropism explains why certain cancers metastasize to specific organs: lung cancer favors brain, bones, and adrenal glands; renal cell carcinoma targets lungs, liver, and bones; pancreatic cancer spreads to liver, stomach, and peritoneum. High mutational burden correlates with increased metastatic potential and responsiveness to targeted therapies.

Metastasis begins with lymphatic dissemination due to vessel permeability and exosome-mediated lymphatic development. Tumor-platelet interactions favor thrombotic events. Extravasation involves selectin-mediated initial adhesion, integrin-mediated stable adhesion, and diapedesis through vessel walls. Organotropism explains why breast cancer metastasizes to bone, colorectal to liver, and pancreatic to liver. The seed and soil theory proposes tumor-derived signals (like PTHrP activating osteoclasts) prepare favorable pre-metastatic niches. Exosomes carrying specific integrins (beta-1 alpha-6 for lung, alpha-v beta-5 for liver) provide molecular specificity for target organ selection. The pre-metastatic niche features high P38 activity, low ERK activity, fibroblasts with easily invaded extracellular matrix, and favorable leukocytes.

The seed and soil hypothesis describes metastasis as interaction between tumor cells and distant organ microenvironments. Cells undergoing partial EMT (hybrid state) are most successful at establishing metastases. Metastatic cells can enter dormancy, surviving 10-15 years without dividing by resisting apoptosis. Organ tropism explains why cancers preferentially metastasize to specific organs: drainage patterns (blood vessel connections) and microenvironment suitability. Pancreatic cancer commonly metastasizes to the liver due to vascular drainage and the liver's growth factor-rich environment.